The next stock on our list here is going to be Novartis. The ticker is NVS. It dropped 12.77% after it disclosed that the uh Pella Carson phase 3 Horizon trial did not meet its primary endpoint.
Selena asked for NVS which has some news here. Frankly, NVS not had a lot of good news recently. Novarta shares trading lower after the company announced that the uh Peloc Carson phase 3 trial did not meet its primary endpoint.
The global phase 3 harbor study evaluating Delerian and people living Sorry. >> No, sorry. I just the the candle finally showed up. So, I just was like reacting to the drop. >> Oh, gotcha.
Okay. So, let me keep going with the news here. Sorry. Didn't mean for that to distract me. Uh, in people living with um monic distrophe type one did not meet its primary endpoint.
More bad data here. 13th reaction tells the story. This drop takes us out of this entire sideways area. I mean, gosh, this goes back to March and we're basically we we did not even we did not even glance at the 200 day.
We went through the 20, 50, 100, and 200 day. We overshot it by a ton. We're we're we've broke this sideways structure that we're in. Stocks down 13% here. 13. What's the trade on this?